Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
HOME > REGULATORY
REGULATORY
- Evrenzo to Add Hypothyroidism Risk in Label Revision
November 17, 2022
- MHLW Unveils Overview of Genome Analysis Project Organ for FY2025 Launch
November 17, 2022
- MHLW to Run Health Survey for COVID-19 Vaccination in Children
November 16, 2022
- LDP Legislators Push for “No Off-Year Price Revision”: Health Committee
November 16, 2022
- LDP Lawmakers Throw Support Behind Pharma on Off-Year Plan
November 15, 2022
- Japan’s 4th Avastin Biosimilar, Kit Products Get Listing; No Follow-On for New API in FY2022
November 15, 2022
- LEO Pharma’s Atopic Dermatitis Med Tralokinumab Up for MHLW Panel Review on November 28
November 15, 2022
- Shionogi’s COVID Pill Up for 3rd Round of Discussion for Emergency Approval on Nov. 22
November 15, 2022
- Teikoku’s Donepezil Tape, AbbVie’s Parkinson’s Med Up for PAFSC Review on Nov. 25
November 14, 2022
- 2 Women Die after BA.5 COVID Booster Shots: MHLW
November 14, 2022
- Kokando Told to Suspend Business for Up to 36 Days over Decades-Long Violations
November 14, 2022
- Online Submissions for Generic Approval to Start from January
November 14, 2022
- Pro-Industry Lawmakers, Govt Remain Widely Divided over Off-Year Plan
November 11, 2022
- MHLW Reserves Extra Budget to Build Gene Therapy Support Consortium
November 11, 2022
- Drug Price Negotiations by Consultants Might Violate Distribution Guidelines: Official
November 11, 2022
- Zero Coefficient Rule Hits All 10 Premium-Granted Drugs Priced by Cost Formula in FY2022
November 11, 2022
- Japan to Roll Out Moderna’s BA.4/5 Booster from Nov. 28
November 11, 2022
- Expert Panel Discussion Summary Reported to Chuikyo; Payer Rep Sees No Need for Inflation Response in Off Year
November 10, 2022
- Polivy Likely to Escape CEA-Based Price Tweaks
November 10, 2022
- MHLW Earmarks 55 Billion Yen for Domestic Antibiotic API Production: Extra Budget
November 10, 2022
ページ
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…